用同源或异源菌株制备的灭活疫苗免疫商品猪对猪鼻支原体感染的保护作用
本研究将属于不同序列型的猪鼻支原体菌株HEF-16和JS-54分别灭活制成疫苗,免疫商品猪后以HEF-16菌株攻毒,比较同源与异源菌株的保护效果。两个免疫组在首次免疫两周后均出现高水平抗体滴度,攻毒后关节病原载量显著下降、平均日增重增加,剖检病变明显减轻。两个免疫组之间临床症状与病理损伤无显著差异,表明灭活疫苗对同源和异源菌株攻毒均具有有效保护。
要点
- 两个免疫组首次免疫两周后均产生高水平抗体滴度。
- 攻毒后免疫组关节病原载量显著下降、平均日增重增加。
- 两个免疫组之间临床症状与病理损伤无显著差异。
核心结论
- 研究证明灭活猪鼻支原体疫苗在商品猪中对同源或异源菌株攻毒均具有有效保护。
- 作者认为灭活菌体疫苗在猪场预防猪鼻支原体相关疾病方面具有有前景的临床应用前景。
研究设计与样本
- 将属于不同序列型的猪鼻支原体菌株HEF-16和JS-54分别灭活制成疫苗。
- 商品猪分别免疫后以HEF-16菌株攻毒,测定并比较同源与异源菌株攻毒的保护效果。
主要发现
- 两个免疫组猪在首次免疫两周后均表现出高水平抗体滴度。
- 攻毒后免疫组关节病原载量显著下降,平均日增重较攻毒组增加。
- HEF-16来源疫苗免疫猪关节肿胀和跛行显著减少,与JS-54来源疫苗免疫猪相似。
- 剖检时攻毒组动物出现中度至重度多发性浆膜炎和关节炎,免疫组病理变化大幅减轻。
- 两个免疫组之间临床症状和病理损伤无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mycoplasma hyorhinis is a highly prevalent pathogen in pig farms worldwide, causing polyserositis and polyarthritis, resulting in great economic losses. Previous genotyping and pathogenic studies have revealed significant genetic and antigenic diversity among M. hyorhinis strains. While there are reports on M. hyorhinis vaccine development, the cross-protection between different M. hyorhinis strains has not been clarified. In this study, two M. hyorhinis strains (HEF-16 and JS-54), belonging to different sequence types, were inactivated to produce vaccines. Pigs were vaccinated respectively and subsequently infected with strain HEF-16. The protection against challenge with homologous or heterologous strains was determined and compared. Both vaccinated groups of pigs exhibited a high antibody titer two weeks after the first vaccination, and significant decreases in pathogen load in joints, along with an increase in average daily weight gain compared to the challenged group after M. hyorhinis challenge. Pigs immunized with the HEF-16-derived vaccine showed a significant reduction in joint swelling and lameness, similar to pigs immunized with the JS-54-derived vaccine. At necropsy, animals in the challenged group exhibited moderate-to-severe polyserositis and arthritis, whereas pathological changes were greatly reduced in animals from the vaccinated groups. No significant differences were observed in clinical symptoms nor pathological damages between the two vaccinated groups. Overall, our study demonstrates the effective protection of the inactivated M. hyorhinis vaccines against challenges with homologous or heterologous strains in commercial pigs. This indicates a promising clinical application prospect for inactivated bacterin vaccines in preventing M. hyorhinis-related diseases in pig farms.
引用
- Wang J, Gan Y, Yuan T, et al. Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains. Vaccine. 2024. PMID: 39388932. doi:10.1016/j.vaccine.2024.126421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。